NASDAQ:ORIC ORIC Pharmaceuticals (ORIC) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free ORIC Stock Alerts $13.75 +0.29 (+2.15%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$13.19▼$14.0750-Day Range$10.02▼$16.0352-Week Range$4.75▼$16.65Volume725,532 shsAverage Volume797,442 shsMarket Capitalization$926.48 millionP/E RatioN/ADividend YieldN/APrice Target$19.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get ORIC Pharmaceuticals alerts: Email Address ORIC Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44.0% Upside$19.80 Price TargetShort InterestBearish10.28% of Shares Sold ShortDividend StrengthN/ASustainability-0.96Upright™ Environmental ScoreNews Sentiment0.71Based on 9 Articles This WeekInsider TradingSelling Shares$169,171 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.76) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.77 out of 5 starsMedical Sector269th out of 939 stocksPharmaceutical Preparations Industry128th out of 444 stocks 3.5 Analyst's Opinion Consensus RatingORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.80, ORIC Pharmaceuticals has a forecasted upside of 44.0% from its current price of $13.75.Amount of Analyst CoverageORIC Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.28% of the outstanding shares of ORIC Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently increased by 6.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldORIC Pharmaceuticals does not currently pay a dividend.Dividend GrowthORIC Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreORIC Pharmaceuticals has received a 69.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for ORIC Pharmaceuticals is -0.96. Previous Next 3.2 News and Social Media Coverage News SentimentORIC Pharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for ORIC Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest6 people have searched for ORIC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows8 people have added ORIC Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ORIC Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $169,171.00 in company stock.Percentage Held by InsidersOnly 5.34% of the stock of ORIC Pharmaceuticals is held by insiders.Percentage Held by Institutions95.05% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ORIC Pharmaceuticals are expected to decrease in the coming year, from ($1.76) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ORIC Pharmaceuticals is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ORIC Pharmaceuticals is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioORIC Pharmaceuticals has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About ORIC Pharmaceuticals Stock (NASDAQ:ORIC)ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More ORIC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORIC Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Lowered to $18.00 at JPMorgan Chase & Co.March 28, 2024 | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Buy" from BrokeragesMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 25, 2024 | americanbankingnews.comORIC Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.46) Per Share, HC Wainwright Forecasts (NASDAQ:ORIC)March 22, 2024 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $21.00 at HC WainwrightMarch 22, 2024 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up After Analyst UpgradeMarch 21, 2024 | markets.businessinsider.comOric Pharmaceuticals: Sustained Buy Rating Amid Strong Financials and Upcoming CatalystsMarch 14, 2024 | investing.comORIC Pharmaceuticals stock target raised to $17 on strong prospectsMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 13, 2024 | seekingalpha.comORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To GainsMarch 12, 2024 | finance.yahoo.comORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial ResultsMarch 12, 2024 | markets.businessinsider.comThese Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 ResultsMarch 11, 2024 | msn.comORIC Pharmaceuticals GAAP EPS of -$0.49March 11, 2024 | globenewswire.comORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational UpdatesMarch 8, 2024 | finance.yahoo.comORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 SharesMarch 7, 2024 | finance.yahoo.comORIC Mar 2024 2.500 putMarch 6, 2024 | finance.yahoo.comORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma ConferenceMarch 6, 2024 | globenewswire.comORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma ConferenceMarch 6, 2024 | globenewswire.comORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma ConferenceMarch 5, 2024 | globenewswire.comORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 3, 2024 | finance.yahoo.comORIC Apr 2024 10.000 callMarch 3, 2024 | finance.yahoo.comORIC Mar 2024 15.000 putMarch 1, 2024 | globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)February 28, 2024 | finanznachrichten.deMadrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial OfficerFebruary 25, 2024 | msn.comCantor Fitzgerald Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight RecommendationFebruary 23, 2024 | msn.comCantor starts ORIC at overweight, cites potential of ORIC-114February 17, 2024 | finance.yahoo.comORIC May 2024 5.000 callSee More Headlines Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ORIC CUSIPN/A CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$19.80 High Stock Price Target$27.00 Low Stock Price Target$13.00 Potential Upside/Downside+44.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.71% Return on Assets-38.55% Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio10.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.33 per share Price / Book4.13Miscellaneous Outstanding Shares67,380,000Free Float63,778,000Market Cap$926.48 million OptionableOptionable Beta1.04 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Richard A. Heyman Ph.D. (Age 67)Co-Founder, Independent Chairman & Member of Scientific Advisory Board Comp: $93kDr. Jacob M. Chacko M.B.A. (Age 45)M.D., President, CEO & Director Comp: $921.32kMr. Dominic G. Piscitelli CPA (Age 49)M.B.A., Chief Financial Officer Comp: $636.91kDr. Pratik S. Multani M.D. (Age 57)M.S., Chief Medical Officer Comp: $686.88kDr. Charles L. Sawyers B.A. (Age 65)M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Scott W. Lowe Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Lori Sickels Friedman Ph.D. (Age 60)Chief Scientific Officer Dr. Christian V. Kuhlen Esq. (Age 51)J.D., M.D., General Counsel Mr. Daniel IazzettiVP & Head of PeopleDr. Edna Chow Maneval (Age 64)Senior Vice President of Clinical Development More ExecutivesKey CompetitorsArcutis BiotherapeuticsNASDAQ:ARQTMacroGenicsNASDAQ:MGNXABIVAX Société AnonymeNASDAQ:ABVXInnovivaNASDAQ:INVAArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 336,350 shares on 3/11/2024Ownership: 3.344%Wellington Management Group LLPBought 72,397 shares on 3/5/2024Ownership: 0.107%Goldman Sachs Group Inc.Bought 2,632 shares on 3/1/2024Ownership: 0.075%Price T Rowe Associates Inc. MDBought 606,446 shares on 2/16/2024Ownership: 0.967%GSA Capital Partners LLPSold 9,503 shares on 2/16/2024Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions ORIC Stock Analysis - Frequently Asked Questions Should I buy or sell ORIC Pharmaceuticals stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares. View ORIC analyst ratings or view top-rated stocks. What is ORIC Pharmaceuticals' stock price target for 2024? 6 analysts have issued twelve-month price objectives for ORIC Pharmaceuticals' shares. Their ORIC share price targets range from $13.00 to $27.00. On average, they predict the company's share price to reach $19.80 in the next year. This suggests a possible upside of 44.0% from the stock's current price. View analysts price targets for ORIC or view top-rated stocks among Wall Street analysts. How have ORIC shares performed in 2024? ORIC Pharmaceuticals' stock was trading at $9.20 on January 1st, 2024. Since then, ORIC shares have increased by 49.5% and is now trading at $13.75. View the best growth stocks for 2024 here. When is ORIC Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ORIC earnings forecast. How were ORIC Pharmaceuticals' earnings last quarter? ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) issued its earnings results on Monday, March, 11th. The company reported ($0.49) EPS for the quarter, hitting analysts' consensus estimates of ($0.49). What other stocks do shareholders of ORIC Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG). When did ORIC Pharmaceuticals IPO? ORIC Pharmaceuticals (ORIC) raised $75 million in an IPO on Friday, April 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO. Who are ORIC Pharmaceuticals' major shareholders? ORIC Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.34%), Vanguard Group Inc. (3.34%), Vivo Capital LLC (1.26%), Price T Rowe Associates Inc. MD (0.97%), Price T Rowe Associates Inc. MD (0.97%) and Point72 Asset Management L.P. (0.77%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller. View institutional ownership trends. How do I buy shares of ORIC Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ORIC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.